Our Mission: Improving and Extending the Lives of Patients with Cancer
  
 
 About Celator®   |   Products   |   CombiPlex®   |   Publications   |   News & Events   |   Contact   |   Home
  General       CPX-351       CPX-1       CPX-571       Nanoparticle Prodrug Delivery       Other
 

Publications: Nanoparticle Prodrug Delivery

Manuscripts

  Modulating the therapeutic activity of nanoparticle-delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates | Ansell et al, J Med Chem 2008 Jun 12; 51(11): 3288-3296

Abstracts
Click abstract title to view poster

  Development of a hydrophobic docetaxel prodrug nanoparticle with enhanced plasma circulation lifetime and improved efficacy | Johnstone et al, American Association for Cancer Research (AACR) Annual Meeting 2010, Abstract #3698
  Development of highly efficacious hydrophobic paclitaxel prodrugs delivered in nanoparticles for fixed-ratio drug combination applications | Ansell et al, American Association for Cancer Research (AACR) Annual Meeting 2008, Abstract #5734

 

 

 

 


CombiPlex® technology is a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit and locks the desired ratio in a nano-scale drug delivery vehicle that delivers and maintains the ratio in patients with the goal of improving clinical outcomes.

 

 

 

 

 

  
© 2009 Celator Pharmaceuticals, Inc. All rights reserved. Celator®, Celator Pharmaceuticals®, the Celator logo and CombiPlex® are registered trademarks of Celator Pharmaceuticals, Inc. Contact webmaster.